Navigation Links
Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
Date:6/27/2008

editable by GSK against outstanding amounts under the loan facility. Exelixis expects to submit the XL184 proof-of-concept package to GSK for its development election in the third quarter of 2008.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's website at http://www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation: statements related to the timing of a phase 3 clinical trial for XL184; the future development and potential efficacy of Exelixis' compounds; the timing of a potential compound selection and milestone payment by GSK; and the timing for submission of the XL184 proof-of-concept package to GSK. Words such as "expect," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current plans, assumptions, beliefs and expectations. Forward- looking statements involve risks and uncertainties. Exelixis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the potential failure of Exelixi
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015 DuPont Executive ... priorities driven by key research advancements and product launches ... today,s Bank of America Merrill Lynch 2015 Global Agriculture ... challenge of building grain supplies the last two years, ... at the pace of the last decade, when demand ...
(Date:2/26/2015)... , Feb. 26, 2015 The healthcare landscape ... ever-changing arena, Frost & Sullivan will host its 20 ... Executive MindXchange , March 8 to 10, at the Hilton ... Calif. This event is a platform ... leaders to discuss industry disruptions and how to succeed in ...
(Date:2/26/2015)... 26, 2015 Innovation is more ... from unexpected parts of the world and transforming ... agriculture to manufacturing to health care, disruption is ... realities and socio-political trends shake the foundations of ... ingredient for CEOs to survive the next wave ...
(Date:2/26/2015)... February 26, 2015 Regis Technologies ... development of oncology drug substances. , Regis Technologies is ... their new Potent Compound Suite (PCS) for 2015. , ... square foot, cGMP facility in Morton Grove, Illinois. The ... of potent compounds up to about one kilogram per ...
Breaking Biology Technology:DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Regis Extends cGMP Services to Oncology Market 2
... , SAN FRANCISCO, Dec. 3 ... focused on the development of compounds for the treatment of ... the last patient visit in its Phase 2 FDG-PET clinical ... patients and was carried out at five sites in the ...
... , TUSTIN, Calif., Dec. 3 Peregrine ... release its financial results for the second quarter of fiscal year ... host a conference call and webcast to discuss the results at ... will discuss financial results for the second quarter ended October 31, ...
... HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, Inc. (Nasdaq: ... for drug discovery and life sciences research, today introduced Living ... Image software drives the more than 800 Caliper IVIS systems ... spectral unmixing tools to enhance fluorescent sensitivity and automated 3D ...
Cached Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Caliper Life Sciences Launches Living Image(R) 4.0 Software 2
(Date:2/9/2015)... -- Lintec of America recently announced an exclusive license to ... including sheets, yarns and ribbons, developed at the University ... vast industrial resources of the global Lintec Group, headquartered ... America is forming the Nano-Science and Technology Center (NSTC) ... scaling up the manufacturing and commercialization of nano engineered ...
(Date:2/5/2015)... Epic Sciences , a precision diagnostics company dedicated to improving ... , Ph.D., president and CEO, is scheduled to present at ... Valley, which is taking place at the Computer History Museum ... 26-28, 2015. Dr. Prahalad will give a ... Epic Sciences was a finalist in the PMWC,s Most Promising ...
(Date:2/5/2015)... FRANCISCO , January 28, 2015 ... Market Analysis, Size And Segment Forecasts To 2020 has ... global IR camera market is expected to reach USD ... by Grand View Research, Inc. IR cameras help identify ... and are expected to witness surging demand in medical ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... HIV, but until recently no one knew how to unlock ... Nature reveals the atomic structure of this weapon ... directions for drug development. APOBEC-3G is present in every ... first step of replication, when the retrovirus transcribes its RNA ...
... we find or share information, but also how we make ... of Health plans to take computer-aided drug design to the ... effort to expand and enhance the molecular data needed to ... The data will be housed in a Web-based resource that ...
... in Plymouth, UK, have carried out research that suggests the ... from health experts may not be enough to tackle the ... published in the most recent issue of the journal "Archives ... EarlyBird study, which has followed the development of over 200 ...
Cached Biology News:Body's anti-HIV drug explained 2New data resource to advance computer-aided drug design 2Recommendations for children's exercise lacking say experts 2
quantitation of phosphatase activity, evaluation of hits and leads from HTS...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
... Services include: ,ISH Protocol Development ... Analyses ,RNA and DNA Screenings ... and Tissues ,Double Labeling of ... and Tissues ,RNA and DNA ...
Biology Products: